A Phase 3, Randomized, Open-Label Study of Upfront Camizestrant Vs Standard Endocrine Therapy As Adjuvant Treatment for ER-positive/HER2negative Early Breast Cancer with Intermediate-High or High Risk of Recurrence (CAMBRIA-2)
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined